Lupin: Lupin Launches Formoflo-G MDI, World's First Fixed-dose Triple Combination Drug for COPD Management
Lupin (LUPIN) filed a disclosure titled "Lupin Launches Formoflo-G MDI, World's First Fixed-dose Triple Combination Drug for COPD Management". The company is valued at about ₹91,986 crore.
What happened
Lupin (LUPIN) filed a disclosure with the exchanges on 6 October 2026 at 09:36 AM titled "Lupin Launches Formoflo-G MDI, World's First Fixed-dose Triple Combination Drug for COPD Management".
Company snapshot
Lupin is a mid-cap company in the Healthcare sector, with a market value of about ₹91,986 crore.
The stock last traded at ₹2,011.8, against a 52-week range of ₹1,900–₹2,529.5 (20.5% below the high).
Before this filing the shares had moved −5.8% over the month and −18.5% over three months. Average daily turnover over the last 20 sessions was about ₹139 crore.
Promoters held 46.85% at the end of Q1 FY27. Foreign institutions owned 22.42% and domestic institutions 24.65%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 6,268 | 1,219 | 26.7 |
| Q2 FY26 | 7,048 | 1,477.9 | 32.36 |
| Q3 FY26 | 7,168 | 1,175.6 | 25.74 |
| Q4 FY26 | 7,475 | 1,460.3 | 31.96 |
| Q1 FY27 | 8,277 | 1,415 | 30.95 |
What history shows
BCEIE's records show 12 or more previous corporate update filings from the company since May 2026.
After those filings, the stock gained 1.1% on average the next trading day and was up 0.8% on average after five days (9 filings with price data).
Market-wide, 64 corporate update filings with an impact score of 50 or more saw an average next-day move of −1.8%, with 27% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 28 Aug 2026 | Corporate update | +1.4% | −2.2% |
| 24 Aug 2026 | ESG Rating by ESG Risk Assessments and Insights Limited. | −0.1% | −1.6% |
| 20 Aug 2026 | Arrangements for strategic, technical, manufacturing, or marketing… | −1.0% | −3.0% |
| 17 Aug 2026 | Corporate update | −0.1% | −2.1% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Lupin share price is currently 'overemphasizing' a risk while 'undermining' a positive, HSBC says
- Lupin Share Price Today, Lupin Stock Price Live NSE/BSE Updates
- Alembic Pharmaceuticals vs Lupin vs FDC Limited: Comparison
- Lupin Announces Completion Of Buyback Of Shares By Multicare Pharmaceuticals Philippines
- Lupin Inaugurates Atharv Ability Neuro-Rehabilitation Center in Delhi, Expanding Specialized Care in North India
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.